LexDanaLexDanabeta
Inventor

Paul Parren

Inventor
Odijk, NL

Overview

96→
Patents
2007–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 96 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary
C07KPeptides27%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations26%
A61KPreparations for medical, dental or toiletry purposes23%
G01NInvestigating or analysing materials by determining their chemical or physical properties12%
C12NMicroorganisms or enzymes7%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests2%
A61NElectrotherapy1%
A01KAnimal husbandry1%
C12YEnzymes1%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture0%
PatentTitleYear
11,130,819Antibodies202111,091,553Monoclonal antibodies against HER2202111,091,557Methods of producing multispecific antibodies against CD40 and CD137202111,084,882Multispecific antibodies against CD40 and CD137202111,046,771Monoclonal antibodies against HER2202111,034,772Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof202111,008,399Antibodies202110,968,280Binding agents binding to PD-L1 and CD137 and use thereof202110,927,181Agonistic tumor necrosis factor (TNF) receptor binding agents202110,906,991Bispecific antibodies and methods for production thereof202110,894,833Agents, uses and methods for treatment202110,889,650Agent, uses and methods for treatment202110,882,913Anti-DR5 antibodies and methods of use thereof202110,865,253Rodent bispecific heterodimeric proteins202010,800,836Agents, uses and methods for the treatment of synucleinopathy202010,793,640Monoclonal antibodies against HER2 epitope202010,765,743Antibodies binding AXL202010,759,867Antibody variants and uses thereof202010,752,695Stable IgG4 antibodies202010,703,818Human monoclonal antibodies against CD25202010,647,763Agents, uses and methods for the treatment of synucleinopathy202010,647,764Agents, uses and methods for the treatment of synucleinopathy202010,640,554Agents, uses and methods for the treatment of synucleinopathy202010,597,464Heterodimeric antibody Fc-containing proteins and methods for production thereof202010,590,206Inert format202010,544,220Bispecific antibodies against CD3 and CD20202010,512,688Antibodies binding AXL201910,500,276Antibodies binding AXL201910,479,835Agent, uses and methods for treatment201910,465,006Humanized or chimeric CD3 antibodies201910,457,735Methods of inducing T cell activation by administering an antibody comprising CD40 and 4-1BB (CD137) binding domains201910,428,147Anti-sortilin antibodies, uses and methods for treatment201910,407,501Humanized or chimeric CD3 antibodies201910,364,285Antibodies for the treatment of synucleinopathy201910,358,483Antibodies for the treatment of synucleinopathy201910,358,484Antibodies for the treatment of synucleinopathy201910,358,482Antibodies for the treatment of synucleinopathy201910,351,629Recombinant IgG4 monovalent antibodies201910,344,050Production of heterodimeric proteins201910,323,081Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains201910,253,093Human monoclonal antibodies against interleukin 8 (IL-8)201910,201,607Antibodies binding AXL201910,155,816Recombinant monovalent antibodies and methods for production thereof201810,066,012Human monoclonal antibodies against interleukin 8 (IL-8)201810,000,570Antibody variants having modifications in the constant region20189,944,711Antibodies against human CD3820189,862,769'Monoclonal antibodies against HER2'20189,714,294'Monoclonal antibodies against HER2 epitope'20179,714,297'Human antibodies against tissue factor and methods of use thereof'20179,695,242'Bispecific EGFR/c-Met antibodies'20179,663,578'Monoclonal antibodies against CD32b'20179,657,107'Monoclonal antibodies against c-Met'20179,598,493'Human monoclonal antibodies against CD25'20179,593,164'Bispecific EGFR/c-Met antibodies'20179,580,508'Bispecific EGFR/c-Met antibodies'20179,580,506'Potency assays for antibody drug substance binding to an Fc receptor'20179,540,433'Human antibodies and antibody-drug conjugates against CD74'20179,540,450'Methods and antibodies for treating cancer'20179,492,565'Human antibody drug conjugates against tissue factor'20169,322,035'Recombinant IgG4 monovalent antibodies'20169,309,315'Therapy with CD4 binding peptides and radiation'20169,249,226'Antibodies against human CD38'20169,212,230'Bispecific antibodies and methods for production thereof'20159,187,565'Antibodies against CD38 for treatment of multiple myeloma'20159,181,344'Use of effector-function-deficient antibodies for treatment of auto-immune diseases'20159,168,314'Human antibody drug conjugates against tissue factor'20159,150,663'Heterodimeric antibody Fc-containing proteins and methods for production thereof'20159,150,658'Human antibodies against tissue factor and methods of use thereof'20159,102,733'Anti-OX40L antibodies'20159,085,625'Antibody variants having modifications in the constant region'20159,068,011'Monoclonal antibodies against c-Met'20159,040,050'Combination treatment of CD38-expressing tumors'20158,961,968'Human monoclonal antibodies against CD25'20158,802,089'Monoclonal antibodies against CD32B'20148,603,469'Methods of treating cancer with human monoclonal antibodies against interleukin 8'20138,529,902'Human monoclonal antibodies against CD20'2013RE044389'Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies'2013RE044359'Nucleic acid molecules encoding anti-P-selectin antibodies'2013RE043568'Anti-P-selectin antibodies'20128,182,812'Human monoclonal antibodies against CD25'20128,105,588'Human monoclonal antibodies against interleukin 8 (IL-8)'20127,868,141'Anti-OX40L antibodies'20117,850,962'Human monoclonal antibodies against CD20'20107,829,673'Antibodies against CD38 for treatment of multiple myeloma'20107,824,684'Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies'20107,807,158'Antibodies against IL-13 receptor alpha1 and uses thereof'20107,754,867'Nucleic acid molecules encoding anti-P-selectin antibodies'20107,622,559'Human monoclonal antibodies against interleukin 8 (IL-8)'20097,579,157'Antibody selection method against IGF-IR'20097,572,897'Antibodies against insulin-like growth factor I receptor and uses thereof'20097,563,441'Anti-P-selectin antibodies'20097,501,496'Anti-OX40L antibodies'20097,473,424'Anti-dengue virus antibodies and compositions'20097,438,907'Human monoclonal antibodies against CD25'20087,378,503'Antibodies against insulin-like growth factor 1 receptor and uses thereof'20087,282,568'Human monoclonal antibodies against interleukin 8 (IL-8)'2007

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2007–2021Patents assigned to GENMAB AS (60)· patent assignee history
2007–2021Based in Odijk, NL· patent location history
2008–2015Based in Odyk, NL· patent location history
2012–2020Patents assigned to PARREN PAUL (28)· patent assignee history
2012–2018Patents assigned to VAN DE WINKEL JAN (17)· patent assignee history
2012–2020Patents assigned to SCHUURMAN JANINE (11)· patent assignee history
2015–2021Based in Utrecht, NL· patent location history
2017Based in Ultrecht, NL· patent location history
2019–2021Patents assigned to H LUNDBECK AS (12)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
GENMAB AS602007–2021
PARREN PAULself282012–2020
VAN DE WINKEL JAN172012–2018
H LUNDBECK AS122019–2021
SCHUURMAN JANINE112012–2020
Locations
LocationPatentsSpan
Odijk, NL602007–2021
Utrecht, NL302015–2021
Ultrecht, NL32017
Odyk, NL32008–2015